Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

136
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
136
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

358
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
358
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

491
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
491
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

1.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
Special considerations while measuring blood pressure01:28

Special considerations while measuring blood pressure

710
When assessing blood pressure (BP), healthcare professionals must consider various factors and potential unexpected outcomes to ensure accurate readings and provide proper patient care. Adhering to these guidelines is essential to achieving the most reliable results.
Monitoring Both Arms:
Monitoring BP in both arms during the initial assessment is advisable, as the systolic value may differ by five to ten mm Hg between arms. For subsequent BP assessments, use the arm with the higher reading.
710

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal MRI sequence for predicting extraprostatic extension in prostate cancer: comparison of LCC and MaxRADD measurements.

Abdominal radiology (New York)·2026
Same author

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

JAMA oncology·2026
Same author

Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance.

European radiology·2026
Same author

Teaching in radical prostatectomy is safe: a multicenter prospective registry analysis.

Journal of robotic surgery·2026
Same author

Nerve-Sparing in High-Risk Prostate Cancer: Advantages and Pitfalls of Current Strategies and Technologies.

Cancers·2026
Same author

En-bloc HoLEP training and learning curve challenges: a multi-generational survey study.

World journal of urology·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

685

[Erectile dysfunction in the hypertensive patient].

Agnese Vella1, Kevin Dobretz1, Massimo Valerio2

  • 1Cardiologie préventive, Service de cardiologie, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14.

Revue Medicale Suisse
|September 12, 2024
PubMed
Summary
This summary is machine-generated.

Erectile dysfunction affects 20-25% of hypertensive patients, often due to atherosclerosis. Management includes lifestyle changes, preferred antihypertensives like ARBs and ACE inhibitors, and PDE5 inhibitors, while avoiding certain diuretics and beta-blockers.

More Related Videos

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

14.2K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.1K

Related Experiment Videos

Last Updated: Jun 13, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

685
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

14.2K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.1K

Area of Science:

  • Cardiology
  • Urology
  • Pharmacology

Background:

  • Erectile dysfunction (ED) is a common comorbidity in hypertensive patients, affecting 20-25% of this population.
  • ED in hypertensive individuals often signifies underlying atherosclerosis, a systemic condition requiring comprehensive management.
  • Current therapeutic strategies for hypertensive patients with ED involve lifestyle modifications and pharmacological interventions.

Purpose of the Study:

  • To outline optimal management strategies for erectile dysfunction in patients with hypertension.
  • To identify antihypertensive medications that are beneficial or detrimental for erectile function.
  • To discuss the role of phosphodiesterase type 5 inhibitors in treating ED in this patient group.

Main Methods:

  • Review of current medical literature on hypertension, erectile dysfunction, and atherosclerosis.
  • Analysis of pharmacological treatments for hypertension, focusing on their effects on erectile function.
  • Evaluation of lifestyle interventions and their impact on both hypertension and ED.

Main Results:

  • Angiotensin 2 receptor antagonists, ACE inhibitors, calcium channel blockers, and nebivolol are preferred antihypertensive agents.
  • Thiazide and thiazide-like diuretics (except indapamide), traditional beta-blockers, and central antihypertensive agents should generally be avoided.
  • Phosphodiesterase type 5 inhibitors are effective pharmacological options for managing ED in hypertensive males.

Conclusions:

  • Tailoring antihypertensive therapy is crucial for managing ED in hypertensive patients.
  • Specific antihypertensive drug classes demonstrate a favorable or unfavorable impact on erectile function.
  • A combination of optimized antihypertensive treatment, lifestyle modifications, and PDE5 inhibitors offers a comprehensive approach to managing ED in hypertensive patients.